Skip to main content
Ambrosia Ventures

Know what your
deal is worth

Stop guessing on upfronts, milestones, and royalties. Benchmark your deal against 2,600+ real transactions in seconds.

2,600+ verified dealsResults in 30 secondsFree to start

See Your Deal Terms Instantly

Select parameters below — benchmarks update in real time

Upfront Payment
$219M - $612M
Median: $393M
Total Deal Value
$1.6B - $3.4B
Median: $2.5B
Royalty Rate
13.4% - 21.9%
Median: 17.6%
Simple Process

How It Works

Get deal term estimates in three simple steps

1

Enter Asset Details

Select therapeutic area, development phase, modality, indication, and other key parameters for your asset.

2

Analyze Market Data

Our algorithm processes your inputs against publicly available deal benchmarks and market data.

3

Get Full Deal Intelligence

Receive instant estimates, rNPV analysis, Monte Carlo simulations, comparable deals, AI deal memos, partner matching, company profiles, and negotiation playbooks.

Why Use This Tool

Built for Life Sciences Professionals

Whether you're a biotech founder, BD executive, or investor, get instant benchmarks for your deals

Deal Benchmarking

Instant benchmarks from 2,600+ real deals across 12 therapeutic areas. Upfront payments, milestones, royalties, and comparable deal matching.

Financial Modeling

Risk-adjusted NPV (rNPV) analysis and Monte Carlo simulation with 10,000 iterations. Model probability-weighted deal outcomes and scenario ranges.

Market Pulse

Weekly market intelligence with benchmark sparklines, deal flow trends, competitive landscape analysis, and market size & epidemiology data.

Company Intelligence

Deep profiles on 850+ pharma and biotech companies with deal history, pipeline tracking, patent cliff timelines, and intelligent partner matching.

Deal Toolkit

AI deal memos, negotiation playbooks, sensitivity analysis, scenario comparison, outreach email generation, and 16-page branded PDF reports.

Enterprise-Grade Platform

GDPR-compliant data handling, authenticated APIs, rate-limited endpoints, WCAG-accessible interface, and weekly SEC EDGAR data ingestion.

Built For You

Every Role, One Platform

From early-stage founders to boardroom advisors, Ambrosia gives you the data edge in every deal conversation

For Founders

  • Know your asset's market value with rNPV analysis and Monte Carlo simulation
  • Present data-backed terms with institutional deal memos and negotiation playbooks
  • Run sensitivity analysis and model scenario ranges before entering the room

For BD Teams

  • Screen opportunities with AI partner matching and company intelligence profiles
  • Generate board-ready PDF reports, AI deal memos, and negotiation playbooks
  • Track deal flow with Market Pulse dashboard and watchlist alerts

For Boards & Investors

  • Validate deal terms with rNPV models and benchmarks from 2,600+ deals across 850+ companies
  • Review Monte Carlo probability distributions and scenario comparisons
  • Monitor market trends with Market Pulse intelligence and deal alerts

For M&A Advisors

  • Accelerate due diligence with rNPV models, comparable deals, and company profiles
  • Build data-driven negotiation strategies with AI playbooks and outreach templates
  • Export branded PDF and Excel reports with full financial modeling for clients

Manual Analysis vs Ambrosia

How institutional deal benchmarking should work

Time to analyze

2-3 weeks
Under 30 seconds

Data coverage

1-2 databases
3,000+ deals from 10+ sources

Financial modeling

Custom Excel models
rNPV + Monte Carlo (10K iterations)

Comparable deals

Hours of manual search
Semantic matching, ranked by similarity

Partner intelligence

Relationship-based
850+ company profiles with deal history

Cost

$5K-$25K per engagement
Free to start
AI Partner Matching

Find Your Ideal Licensing Partner

Our AI matches your asset profile against 850+ pharma and biotech companies to find the best strategic fit

Run analysis to reveal
92%
Major Pharma Co.
Oncology, ADC expertise
12 deals in 12mo
Run analysis to reveal
87%
Global BioPharma
Late-stage licensing
8 deals in 12mo
Run analysis to reveal
84%
Specialty Pharma
Niche indications
6 deals in 12mo
Advanced Analytics

Beyond Benchmarks

Full financial modeling and market intelligence tools that turn data into deal strategy

rNPV & Monte Carlo Simulation

Risk-adjusted net present value analysis with 10,000-iteration Monte Carlo simulation. Model probability-weighted deal outcomes across development phases, regulatory milestones, and commercial scenarios.

Phase-gated probabilitiesConfidence intervalsScenario rangesWaterfall charts

Market Pulse Intelligence

Real-time market intelligence dashboard with benchmark sparklines, deal flow trends by modality, competitive landscape analysis, and market size & epidemiology data across therapeutic areas.

Benchmark trendsDeal flow chartsCompetitive landscapeMarket sizing

Company Profiles & Pipeline

Deep profiles on 850+ pharma and biotech companies with historical deal flow, active pipeline tracking from ClinicalTrials.gov, patent cliff timelines, and strategic fit scoring.

Deal historyPipeline trackerPatent cliffsStrategic fit scores

Advanced Deal Intelligence

Institutional-grade deal memos, negotiation playbooks with counterparty-specific tactics, outreach email templates, and 16-page branded PDF reports — all customized to your specific asset and market position.

Deal memosNegotiation playbooksOutreach emailsDeal reports

Built for Life Sciences Deal-Making

Benchmarks derived from 2,600+ publicly disclosed licensing deals sourced from SEC filings and press releases. Updated weekly with new transactions.

📄
SEC EDGAR 8-K Filings
Primary deal data extracted from regulatory filings
🔬
ClinicalTrials.gov
Pipeline and trial data for partner intelligence
📊
Weekly Updates
New deals ingested every Monday at 4AM UTC
🔒
Enterprise Security
GDPR-compliant, authenticated APIs, encrypted data
About Us

Ambrosia Ventures

A boutique strategy and M&A advisory firm specializing in life sciences. We help biotech companies, pharmaceutical corporate development teams, and investors navigate licensing deals, M&A transactions, and strategic partnerships.

Licensing StrategyM&A AdvisoryIn/Out-LicensingDeal StructuringValuation
Visit Our Website